“Shutting Down Pain” Video In this video, learn more more about how Genentech scientists teamed up with the Xenon team to develop a new tool that could be a game changer in the way we treat all forms of pain.
Nav1.7 Inhibitors for Pain
Selective Inhibitors of NaV1.7 for the Treatment of Pain
Based on our discovery of NaV1.7 deficiency underlying the rare human disease called congenital indifference to pain, or CIP, where individuals with CIP are unable to feel pain, we believe that NaV1.7 is a highly-validated target for the treatment of pain.
Chronic pain conditions, such as severe cancer pain and neuropathic pain, are generally recognized as unmet medical needs providing potential commercial opportunities for a new oral pain drug. Currently available pain drugs often have either a lack of meaningful pain relief or dose limiting side effects for many patients. An orally administered selective NaV1.7 inhibitor could present a novel mechanism for the treatment of moderate to severe pain as a single agent or in combination with existing analgesics that work through different mechanisms. We believe that the selective inhibition of NaV1.7 may lower the potential for dose-limiting central nervous system side-effects and allow for an improved side-effect profile for oral administration of such an inhibitor, which could potentially allow for the treatment of pain that has a central or deep tissue component, including cancer pain and neuropathic pain.
In December 2011, we entered into a collaborative research and license agreement with Genentech, a member of the Roche Group, to discover and develop selective oral inhibitors of NaV1.7 for the treatment of pain. This ongoing collaboration with Genentech is focused on developing novel inhibitors of NaV1.7 for the treatment of pain.
In September 2019, Xenon entered into a definitive agreement with Flexion Therapeutics giving them the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain. Flexion’s new preclinical program, known as FX301, is a locally administered NaV1.7 inhibitor formulated for extended-release from a thermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain. FX301 has the potential to provide effective pain relief while preserving motor function. The company anticipates initiating FX301 clinical trials in 2021.